Close Menu

Scripps Genomic Medicine

The R&D deal targets oncology and cardiovascular disease.

The study, which surveyed more than 2,000 people, found that the "results of a direct-to-consumer genomic risk test do not affect health-related behavior."

A survey primarily using Scripps employees and Navigenics test offering shows that 50 percent of DTC genomics test takers have concerns, but over 80 percent want to know risks even of non-preventable diseases.

"We are concentrating on two initial areas — diabetes and aging research," Eric Topol, chief academic officer of Scripps Health, said. "Diabetes PGx work is of vital interest to Scripps, Sanofi, and the public."

Under terms of the alliance, a Sanofi-aventis Group subsidiary will fund each year up to three Discovery Innovation Grants intended to offer flexible financing for innovative research proposals from investigators at a division of Scripps Health.

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.